Quick answer
Zurich Biotech ships lyophilized research peptides to all Jakarta addresses and surrounding Greater Jabodetabek areas, typically within one business day. Jakarta is Indonesia's main cold-chain distribution center, meaning most domestic pharmaceutical shipments originate here rather than transiting through another island. BPOM Regulation No. 27 of 2022 (as amended by Regulation No. 8 of 2024) governs research-use imports of unregistered pharmaceuticals through the Special Access Scheme, and that framework applies to research peptides received anywhere in Indonesia, including Jakarta.
BPOM and the regulatory framework for research imports
BPOM (Badan Pengawas Obat dan Makanan) is Indonesia's national authority for drug and food oversight. Any pharmaceutical product without a domestic Marketing Authorization must enter through a licensed channel. For research purposes, that channel is the Special Access Scheme (SAS), which covers research, clinical development, and other non-commercial scientific uses.
Research peptides are not classified as narcotics or psychotropics under Indonesian law, so they follow the standard SAS route rather than any more restrictive pathway. BPOM Regulation No. 8 of 2024, issued alongside Government Regulation No. 28 of 2024 implementing Law No. 17 of 2023 on Health, introduced a digital processing track for SAS authorizations, reducing administrative turnaround time for research-use imports.
For a researcher receiving a shipment at a Jakarta address, the SAS authorization sits with the importing entity, not the individual. The researcher takes delivery of a research-use compound already covered by that authorization. Orders ship with a Certificate of Analysis; the COA guide covers what to verify on receipt.
Shipping within Jakarta and Greater Jabodetabek
Jakarta concentrates Indonesia's pharmaceutical cold-chain infrastructure. The city's logistics belt runs from the Tanjung Priok port area in North Jakarta through the warehouse-dense Cakung and Cibitung corridors in East Jakarta and Bekasi, and south toward BSD City in Tangerang Selatan. Indonesia's cold-chain logistics sector reached approximately USD 7.2 billion in 2025 and is expanding at about 9.5% per year, with Jakarta-based facilities handling the majority of domestic pharmaceutical outbound volume.
Same-day or next-day delivery covers all five Jakarta municipalities. Outer Jabodetabek areas also receive orders within one to two business days: South Jakarta (Kebayoran Baru, Pondok Indah, Cilandak, Fatmawati, TB Simatupang corridor), Central Jakarta (Menteng, Gambir, Tanah Abang, Salemba), West Jakarta (Grogol, Slipi, PIK, Puri Indah), East Jakarta (Cawang, Cibubur, Rawamangun), North Jakarta (Pluit, Sunter, Kelapa Gading), and further out to BSD City, Serpong, and Tangerang Selatan in Banten, plus Depok and Bekasi in West Java.
Apartment and serviced-office towers in the CBD corridors (SCBD, Mega Kuningan, Sudirman) accept deliveries through building management. Cluster housing in the southern suburbs and satellite towns uses standard residential courier procedures. Clinic and hospital addresses across the metropolitan area work without any special requirements.
Climate and storage requirements in Jakarta
Jakarta falls in ICH Climatic Zone IVb, the hot-and-very-humid classification that sets pharmaceutical stability testing conditions at 30°C and 75% relative humidity. Year-round ambient temperatures average 26 to 32°C, with relative humidity running 67 to 76% throughout the year. The wet season, roughly October through May, pushes humidity toward the upper end of that range.
Lyophilized peptides absorb moisture when exposed to ambient air under these conditions. A 2015 stability study published in the International Journal of Pharmaceutics (Srinivasan et al., Int J Pharm 2015) measured a 20 to 27% decrease in peptide concentration at 25°C and 60% relative humidity over 8 weeks, along with measurable particulate formation in reconstituted samples. Jakarta's ambient conditions exceed both test parameters for most of the year.
Lyophilized vials should go into a freezer at -20°C or colder on receipt. A multi-site consensus on clinical peptide handling published in Clinical Chemistry (Hoofnagle et al., multi-site consortium, Clin Chem 2016) recommends -20°C storage and limiting freeze-thaw cycles to preserve compound integrity. A standard household or lab freezer at -18°C meets this requirement for most compounds over a 6 to 12-month research window.
Reconstituted peptide goes into the refrigerator at 2 to 8°C and should not sit at room temperature between uses. Power stability in Jakarta is generally reliable across the city, but the outer Jabodetabek ring, particularly outer Bekasi and parts of Depok, experiences occasional grid disruptions. A small UPS on the research freezer protects against brief outages without requiring generator infrastructure. A full storage protocol, including freeze-thaw limits, desiccant use, and compound-specific guidance, is in the article on lyophilized peptide storage in tropical climates.
Research environment in Jakarta
Jakarta has the largest concentration of pharmaceutical and biomedical research infrastructure in Indonesia. Universitas Indonesia's Faculty of Pharmacy (Departemen Farmasi FKUI) in Salemba, Central Jakarta, is the country's most-cited pharmaceutical sciences program, with active work in pharmacokinetics, formulation, and stability research. Cipto Mangunkusumo Hospital, the national referral center adjacent to FKUI, serves as the clinical anchor for the university's trial programs.
OUCRU Indonesia (Oxford University Clinical Research Unit) operates in partnership with Universitas Indonesia and runs translational research programs in infectious disease and clinical pharmacology. Several contract research organizations opened Jakarta offices between 2022 and 2024, adding commercial research capacity to an already active academic environment.
The BSD City and Serpong corridor in Tangerang Selatan has drawn private biotech and clinical research facilities since 2020, making South Tangerang an emerging secondary node for peptide research activity within the Greater Jakarta area. Researchers based there receive orders on the same delivery timeline as central Jakarta addresses.
Research peptides ordered in Jakarta
Tissue repair compounds account for the largest share of Jakarta orders. BPC-157 and TB-500 together make up the plurality of vials ordered from Jakarta, reflecting a mix of academic researchers and private clinic operators running investigational protocols. Jakarta's private wellness and longevity clinic sector, concentrated in South Jakarta and the CBD, orders a higher proportion of metabolic peptide protocols than comparable Bali or Surabaya markets.
GHK-Cu and MOTS-c orders come from both dermatology clinics and independent skin biology researchers, with the Menteng and Sudirman clinic corridor showing the highest concentration of aesthetic research orders in the city. Retatrutide, the triple GLP-1/GIP/glucagon agonist currently in Phase 3 trials, is the fastest-growing compound by order volume in Jakarta, reflecting the city's concentration of metabolic medicine researchers and private obesity clinics.
For dosing calculations on any compound, the peptide dosing calculator handles reconstitution math for all standard vial concentrations and U-100 syringe measurements.